Emerald Advisers LLC lessened its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 72.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,517 shares of the specialty pharmaceutical company’s stock after selling 6,775 shares during the quarter. Emerald Advisers LLC’s holdings in Jazz Pharmaceuticals were worth $312,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in JAZZ. FMR LLC increased its stake in Jazz Pharmaceuticals by 12.1% in the 2nd quarter. FMR LLC now owns 6,634,958 shares of the specialty pharmaceutical company’s stock valued at $1,143,203,000 after buying an additional 715,595 shares during the period. Scout Investments Inc. acquired a new position in Jazz Pharmaceuticals in the 4th quarter valued at approximately $54,686,000. AQR Capital Management LLC increased its stake in Jazz Pharmaceuticals by 156.6% in the 3rd quarter. AQR Capital Management LLC now owns 344,313 shares of the specialty pharmaceutical company’s stock valued at $57,889,000 after buying an additional 210,156 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Jazz Pharmaceuticals by 14.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,690,385 shares of the specialty pharmaceutical company’s stock worth $284,205,000 after purchasing an additional 207,954 shares during the last quarter. Finally, Victory Capital Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 1,894.1% during the 3rd quarter. Victory Capital Management Inc. now owns 202,000 shares of the specialty pharmaceutical company’s stock worth $33,962,000 after purchasing an additional 191,870 shares during the last quarter. Hedge funds and other institutional investors own 92.16% of the company’s stock.

NASDAQ JAZZ opened at $128.35 on Friday. The company has a quick ratio of 4.16, a current ratio of 4.29 and a debt-to-equity ratio of 0.52. The firm has a market cap of $7.74 billion, a P/E ratio of 11.11, a PEG ratio of 0.78 and a beta of 1.17. Jazz Pharmaceuticals PLC has a 1 year low of $113.52 and a 1 year high of $184.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.32 by $0.26. The business had revenue of $469.37 million during the quarter, compared to the consensus estimate of $482.64 million. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. Jazz Pharmaceuticals’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.22 EPS. On average, equities research analysts expect that Jazz Pharmaceuticals PLC will post 11.66 earnings per share for the current year.

In related news, CFO Matthew P. Young sold 700 shares of the company’s stock in a transaction on Friday, November 23rd. The shares were sold at an average price of $150.00, for a total transaction of $105,000.00. Following the completion of the sale, the chief financial officer now directly owns 32,068 shares of the company’s stock, valued at approximately $4,810,200. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Seamus Mulligan purchased 50,000 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, November 15th. The stock was bought at an average cost of $144.56 per share, with a total value of $7,228,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 4,234 shares of company stock valued at $602,314. 3.90% of the stock is owned by insiders.

Several brokerages have recently commented on JAZZ. BidaskClub upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, January 7th. Zacks Investment Research restated a “hold” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, November 13th. Morgan Stanley set a $168.00 price target on shares of Jazz Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 28th. Wells Fargo & Co restated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Sunday, December 23rd. Finally, Mizuho dropped their price target on shares of Jazz Pharmaceuticals to $157.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 20th. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $190.35.

ILLEGAL ACTIVITY NOTICE: “Emerald Advisers LLC Reduces Holdings in Jazz Pharmaceuticals PLC (JAZZ)” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2019/02/03/emerald-advisers-llc-reduces-holdings-in-jazz-pharmaceuticals-plc-jazz.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: Trading Strategy Methods and Types

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.